Johns Hopkins Medicine researchers have identified a protein—DMBT1S8—as a target for potential therapies to treat inflammation in the nasal and sinus cavities.
Nasal and sinus inflammation—known medically as chronic rhinosinusitis—is one of the most common chronic illnesses in the United States, according to the U.S. Centers for Disease Control and Prevention. But for people with the most severe form of the condition, chronic rhinosinusitis with nasal polyps, it isn't your average stuffy nose.
Patients with this disorder are more susceptible to developing nasal obstruction, asthma or asthma like symptoms, sleep apnea, or loss of taste and smell. Corticosteroids are sometimes prescribed to treat severe forms, but are known to have dangerous side effects if used too long.
hopkinsmedicine.org/news/ne...
Glycobiology (2021). Research Paper:
